Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type ALK, Wild type EGFR status confers therapeutic sensitivity to Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel in patients with Non-Small Cell Lung Cancer.
The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
This statement is based on a regulatory approval from the Food and Drug Administration:
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.